Dialysis Access Malfunction, Kidney Failure
Conditions
Brief summary
Recent studies of paclitaxel DCB in the treatment of stenosis at dialysis vascular access have shown promising results. Paclitaxel, an anti-proliferation drug, is released during balloon inflation and potentially improve primary patency by slowing down NIH effect. However, meta-analysis have suggested that the use of paclitaxel in lower limbs have increased risk of death in patients. The effect of paclitaxel DCB on dialysis access however remains unknown. Hence, we aim to set up a database to track long-term treatment outcomes of patients treated with Paclitaxel DCB at SGH for their stenosed dialysis access
Interventions
Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
Sponsors
Singapore General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Inclusion criteria
* All patients above 21 that is undergoing AVF/AVG fistuloplasty with paclitaxel DCB at SGH is included
Exclusion criteria
* All patients below 21
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Circuit Access Patency | 12 Months | Circuit Access Patency is lost when AVF/AVG is intervened on |
| Primary Assisted Patency | 12 months | Primary Assisted Patency is lost when circuit undergoes thrombectromy/thrombolysis |
| Secondary Patency | 12 months | Secondary Patency is lost when entire dialysis access circuit is abandoned. |
Countries
Singapore
Contacts
Primary ContactCharyl Yap
Outcome results
None listed